The global neurological biomarkers market is experiencing significant growth as healthcare providers, pharmaceutical companies, and research organizations increasingly recognize the importance of accurate disease detection and personalized treatment. Neurological Biomarkers Market help identify disease-related biological changes, assess disease progression, estimate patient risk, and monitor...
The global molecular diagnostics market is witnessing steady expansion as healthcare providers increasingly prioritize early disease detection, accurate diagnosis, and personalized treatment. The Molecular Diagnostics Market was valued at USD 18.8 billion in 2025 and is projected to increase from USD 19.4 billion in 2026 to USD 25.6 billion by 2033, registering a CAGR of 4.1% from 2026 to 2033....
The global Molecular Cytogenetics Market was estimated at USD 2.40 billion in 2024 and is projected to reach USD 6.39 billion by 2033, expanding at a CAGR of 11.7% from 2025 to 2033. Market growth is driven by the increasing application of molecular cytogenetic techniques in clinical diagnostics and research, particularly for oncology, genetic disorders, and prenatal testing. The growing use of...
The global clinical laboratory tests market was valued at USD 145.66 billion in 2025 and is projected to grow from USD 155.11 billion in 2026 to USD 256.52 billion by 2034 , registering a CAGR of 6.49% during 2026-2034 . North America dominated the market with a 42.5% share in 2025 , while Asia Pacific is expected to register the fastest CAGR of 8.3% during the forecast period.
Market Size...
Mass spectrometry is moving beyond its traditional role as a laboratory analytical technique and becoming an increasingly important part of pharmaceutical research, biotechnology, proteomics, diagnostics, and other molecular investigations. The global Mass Spectrometry Market was valued at USD 7.3 billion in 2025 and is projected to reach USD 13.2 billion by 2033, expanding at a CAGR of 7.6%...
Overview:
The Cell Surface Markers Market is expanding as biomedical research increasingly relies on accurate identification and characterization of different cell populations. Cell surface markers are proteins, glycoproteins, and other molecules expressed on cell membranes that help researchers distinguish cell types, evaluate cellular states, and understand biological functions. The market...
The global computational biology market was valued at USD 7.08 billion in 2025 and is projected to grow from USD 7.99 billion in 2026 to USD 21.07 billion by 2034 , recording a CAGR of 12.88% during 2026-2034 . North America dominated the market with a 39.8% share in 2025 , while Europe is expected to register the fastest CAGR of 18.91% .
Market Size (2025): USD 7.08 Billion
Market...
The global breast biopsy market was valued at USD 2.83 billion in 2025 and is projected to grow from USD 3.14 billion in 2026 to USD 7.12 billion by 2034 , recording a CAGR of 10.8% during 2026-2034 . North America dominated the market with a 38.6% share in 2025 , while Asia Pacific is expected to register the fastest CAGR of 9.18% .
Market Size (2025): USD 2.83 Billion
Market Size...
The role of proteomics is changing as life sciences research moves toward more detailed and personalized understanding of biology. Instead of examining proteins in isolation, researchers are increasingly looking at expression patterns, interactions, biomarkers, and molecular pathways to understand disease and therapeutic response. This broader role is creating new demand for technologies that...
The biosensors market is no longer confined to traditional diagnostic laboratories. Sensors that interact with biological signals are appearing in wearable devices, point-of-care systems, research platforms, food analysis, agriculture, environmental monitoring, and other specialized applications. This diversification is giving the industry a wider commercial base while healthcare continues to...
The companion diagnostics market is becoming an increasingly important link between diagnosis and treatment. Instead of asking only whether a disease is present, modern healthcare is increasingly asking a more specific question: which therapy is most appropriate for this patient? That change is reshaping the role of diagnostics. A biomarker can now influence whether a targeted drug is...
Cancer research has traditionally depended heavily on controlled clinical trials, but the treatment experience that occurs outside those trials is generating an increasingly valuable source of evidence. Patients receive different therapies, move between care settings, respond differently to treatment, and experience outcomes over long periods that may not always be fully captured within...